BioNTech SE (BioNTech SE) Net Margin % : 30.96% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. BioNTech SE's Net Income for the three months ended in Dec. 2023 was $499 Mil. BioNTech SE's Revenue for the three months ended in Dec. 2023 was $1,613 Mil. Therefore, BioNTech SE's net margin for the quarter that ended in Dec. 2023 was 30.96%.

The historical rank and industry rank for BioNTech SE's Net Margin % or its related term are showing as below:

BNTX' s Net Margin % Range Over the Past 10 Years
Min: -164.92 Med: 3.15 Max: 54.5
Current: 24.34

BNTX's Net Margin % is ranked better than
91.43% of 1027 companies
in the Biotechnology industry
Industry Median: -160.92 vs BNTX: 24.34

BioNTech SE Net Margin % Historical Data

The historical data trend for BioNTech SE's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Net Margin % Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-164.92

3.15

54.24

54.50

24.36

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															53.26	39.33	-113.54	17.94	30.96

Competitive Comparison of BioNTech SE's Net Margin %

For the Biotechnology subindustry, BioNTech SE's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNTech SE's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's Net Margin % distribution charts can be found below:

* The bar in red indicates where BioNTech SE's Net Margin % falls into.

BioNTech SE Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

BioNTech SE's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	1014.504	/	4164.667
	=	24.36 %

BioNTech SE's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	499.346	/	1612.868
	=	30.96 %

BioNTech SE (NAS:BNTX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

BioNTech SE Net Margin % Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.